论文部分内容阅读
目的探讨注射用胸腺法新治疗硅沉着病的临床疗效及其对患者免疫功能的影响。方法选取上海市龙华医院浦东分院2014年5月—2016年1月收治的硅沉着病患者60例,根据治疗方案的不同分为对照组和观察组,各30例。患者入院后均给予常规基础治疗,对照组患者给予汉防己甲素治疗,观察组患者给予注射用胸腺法新治疗,两组患者均持续治疗3个月。比较两组患者胸闷、胸痛、呼吸困难、咳嗽、咳痰好转情况及T淋巴细胞亚群(CD_3~+细胞分数、CD_4~+细胞分数、CD_8~+细胞分数、CD_4~+/CD_8~+细胞比值)、免疫球蛋白(IgM、IgG、IgA)水平。结果观察组患者胸闷、胸痛、呼吸困难、咳嗽、咳痰好转率高于对照组(P<0.05)。治疗后,观察组患者CD_3~+细胞分数、CD_4~+细胞分数、CD_4~+/CD_8~+细胞比值高于对照组,CD_8~+细胞分数低于对照组(P<0.05)。观察组患者IgM、IgG、IgA高于对照组(P<0.05)。结论注射用胸腺法新治疗硅沉着病的临床疗效确切,可有效改善机体肺功能,提高细胞免疫力。
Objective To investigate the clinical efficacy of thymus injection in the treatment of silicosis and its effect on immune function. Methods Sixty patients with silicosis who were admitted to Shanghai Pudong Branch of Longhua Hospital from May 2014 to January 2016 were divided into control group and observation group according to the different treatment regimen. Patients were given routine basic treatment after admission, patients in the control group were treated with tetrandrine, patients in the observation group were treated with thymus injection, and both groups were treated for 3 months. Chest tightness, chest tightness, dyspnea, cough, sputum improvement and T lymphocyte subsets (CD_3 ~ + cell fraction, CD_4 ~ + cell fraction, CD_8 ~ + cell fraction, CD_4 ~ + / CD_8 ~ + cells Ratio), immunoglobulin (IgM, IgG, IgA) levels. Results The improvement rates of chest tightness, chest pain, dyspnea, cough and sputum in observation group were higher than those in control group (P <0.05). After treatment, the percentage of CD_3 ~ + cells, CD_4 ~ + cells and CD_4 ~ + / CD_8 ~ + cells in the observation group were higher than those in the control group, while the scores of CD_8 ~ + cells in the observation group were lower than those in the control group (P <0.05). IgM, IgG and IgA in observation group were higher than those in control group (P <0.05). Conclusion The new thymus injection in the treatment of silicosis is clinically effective and can effectively improve the lung function and improve cellular immunity.